Lv4
560 积分 2025-06-27 加入
Mitigation of pre-existing immunogenicity in ADA method development
2天前
已完结
Augmenting immunogenicity workflows with AI and real-world evidence: failure points, tools, and a closed-loop operational blueprint
2天前
已完结
Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics
2天前
已完结
Bioanalysis for PK for antibody drug conjugates using ligand binding assay–challenges and bioanalytical strategies
1个月前
已完结
The role of Ligand-Binding Assay and LC–MS in the Bioanalysis of Complex Protein and Oligonucleotide Therapeutics
1个月前
已完结
The Global, Regional, and National Burden of Nonrheumatic Valvular Heart Disease in 204 Countries and Territories, 1990–2021: Insights from the Global Burden of Disease Study 2021
1个月前
已完结
Immunogenicity risk mitigation of therapeutic proteins with translational immunogenicity, analytical characterization, and regulatory insight
2个月前
已完结
Modeling human immune responses to vaccination in vitro
2个月前
已完结
Human Artificial Lymph Node Model (HuALN)
2个月前
已完结
Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance
2个月前
已完结
皖公网安备34019202002308
